ResVerlogix cholesterol drug fails mid-stage trial

Nov 17 (Reuters) - ResVerlogix's experimental drug failed to achieve its main goal of increasing production of protein associated with good cholesterol and clear plaque from arteries, sending its shares down as much as 45 percent.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.